Prevention of Peritransplantation Viridans Streptococcal Bacteremia with Early Vancomycin Administration: A Single‐Center Observational Cohort Study
| Autor: | Kent A. Sepkowitz, Dana Jaffe, Eric G. Pamer, Genovefa A. Papanicolaou, Timothy E. Kiehn, R. Sebti, Ann A. Jakubowski |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male Microbiology (medical) medicine.medical_specialty Time Factors Adolescent Bacteremia Cohort Studies Risk Factors Vancomycin Streptococcal Infections Internal medicine Humans Medicine Risk factor Child Aged Antibacterial agent business.industry Incidence (epidemiology) Hazard ratio Hematopoietic Stem Cell Transplantation Infant Antibiotic Prophylaxis Middle Aged Viridans Streptococci Anti-Bacterial Agents Surgery Transplantation Infectious Diseases Child Preschool Cohort Female business medicine.drug Cohort study |
| Zdroj: | Clinical Infectious Diseases. 39:1625-1632 |
| ISSN: | 1537-6591 1058-4838 |
| DOI: | 10.1086/425612 |
| Popis: | Background. Viridans streptococcal bacteremia (VSB) after allogeneic hematopoietic stem cell transplantation (HSCT) is associated with substantial mortality. Prevention of this serious complication is therefore a high priority. The objective of this study was to evaluate the effect of early vancomycin administration on rates and outcomes of VSB. Methods. We analyzed the effect of early vancomycin on the incidence of VSB in a cohort of 430 consecutive HSCTs performed during the period of 1 January 1998 to 30 September 2002. The primary end point was time to diagnosis of VSB. Early vancomycin was defined as ≥2 doses of vancomycin between days -7 through +7 after HSCT or diagnosis of VSB, whichever occurred first. Risk factors for VSB were identified in univariate and multivariate Cox proportional hazard models. Results. The incidence of VSB in the cohort was 7.4%. The incidence of VSB in patients who did not receive early vancomycin was 24.8%, compared with 0.3% in patients who did (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|